T/FIF Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (901)	5/25/1999 7:13:00 PM
From: Pseudo Biologist	Read Replies (1) of 1073

Interesting, naively, it seems to me that the Biogen molecule (a LFA3 fusion with an antibody constant region) is not that different from an anti-CD2 antibody (like BTRN+MEDI's), given that the LFA3 molecule binds to CD2 (a similar relation may exist between IMNX's Enbrel and CNTO's Ramicade). Maybe Rick can comment and explain why this news should make BTRN go up 10 bucks too -g- PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next